Project MOTION
@crgmotion.bsky.social
Clinical Research Group MOTION at MUW (Medical University Vienna)
funded by @lbg.ac.at
Focusing on disease-driving mechanisms in patients with #PortalHypertension
#LiverFibrosis
funded by @lbg.ac.at
Focusing on disease-driving mechanisms in patients with #PortalHypertension
#LiverFibrosis
🌟 Exciting times for our MOTION team!
We’re growing and evolving as we enter Year 3 — with new roles, fresh perspectives & shared dedication to advance hepatology and improve patient outcomes.
💪 Here’s to another year of teamwork & innovation!
#MOTIONTeam #LiverResearch
We’re growing and evolving as we enter Year 3 — with new roles, fresh perspectives & shared dedication to advance hepatology and improve patient outcomes.
💪 Here’s to another year of teamwork & innovation!
#MOTIONTeam #LiverResearch
October 23, 2025 at 10:53 AM
🌟 Exciting times for our MOTION team!
We’re growing and evolving as we enter Year 3 — with new roles, fresh perspectives & shared dedication to advance hepatology and improve patient outcomes.
💪 Here’s to another year of teamwork & innovation!
#MOTIONTeam #LiverResearch
We’re growing and evolving as we enter Year 3 — with new roles, fresh perspectives & shared dedication to advance hepatology and improve patient outcomes.
💪 Here’s to another year of teamwork & innovation!
#MOTIONTeam #LiverResearch
🎉 Congrats to Mathias Jachs, MD, PhD on completing his Habilitation at MedUni Vienna — an impressive milestone at such a young age! 👏
His lecture covered liver cirrhosis, CSPH & hepatitis B/D.
💪 We’re proud to have him on our MOTION team!
#Hepatology
His lecture covered liver cirrhosis, CSPH & hepatitis B/D.
💪 We’re proud to have him on our MOTION team!
#Hepatology
October 10, 2025 at 10:17 AM
🎉 Congrats to Mathias Jachs, MD, PhD on completing his Habilitation at MedUni Vienna — an impressive milestone at such a young age! 👏
His lecture covered liver cirrhosis, CSPH & hepatitis B/D.
💪 We’re proud to have him on our MOTION team!
#Hepatology
His lecture covered liver cirrhosis, CSPH & hepatitis B/D.
💪 We’re proud to have him on our MOTION team!
#Hepatology
🩸Next - WP6: Coagulation & Hemostasis Research
Our specialists is working to characterize rebalanced hemostasis in #ACLD & #PSVD using advanced diagnostics like #ClotPro & TM-TGA.
#Portalhypertension #coagulation #liver #Clinicaltrial
Our specialists is working to characterize rebalanced hemostasis in #ACLD & #PSVD using advanced diagnostics like #ClotPro & TM-TGA.
#Portalhypertension #coagulation #liver #Clinicaltrial
October 10, 2025 at 6:57 AM
🩸Next - WP6: Coagulation & Hemostasis Research
Our specialists is working to characterize rebalanced hemostasis in #ACLD & #PSVD using advanced diagnostics like #ClotPro & TM-TGA.
#Portalhypertension #coagulation #liver #Clinicaltrial
Our specialists is working to characterize rebalanced hemostasis in #ACLD & #PSVD using advanced diagnostics like #ClotPro & TM-TGA.
#Portalhypertension #coagulation #liver #Clinicaltrial
After a long summer break, we continue introducing our work packages of project MOTION.
UP next is WP5 introduced and led by
@mathiasjachs.bsky.social
🖐️
Developing prognostic #NIT models for #ACLD or #PSVD
📷More info in the video below 📷
UP next is WP5 introduced and led by
@mathiasjachs.bsky.social
🖐️
Developing prognostic #NIT models for #ACLD or #PSVD
📷More info in the video below 📷
September 26, 2025 at 6:24 AM
After a long summer break, we continue introducing our work packages of project MOTION.
UP next is WP5 introduced and led by
@mathiasjachs.bsky.social
🖐️
Developing prognostic #NIT models for #ACLD or #PSVD
📷More info in the video below 📷
UP next is WP5 introduced and led by
@mathiasjachs.bsky.social
🖐️
Developing prognostic #NIT models for #ACLD or #PSVD
📷More info in the video below 📷
🙌We wrapped up an amazing MOTION annual meeting! 🙌
Reflected on 2 years of growth & scientific insights, and set course for the next 2 years.
Next step: making our 3 clinical trials – and project MOTION as a whole – an outstanding success! 💫
#MotionProject #TeamScience #ClinicalTrials
Reflected on 2 years of growth & scientific insights, and set course for the next 2 years.
Next step: making our 3 clinical trials – and project MOTION as a whole – an outstanding success! 💫
#MotionProject #TeamScience #ClinicalTrials
September 19, 2025 at 7:23 AM
🙌We wrapped up an amazing MOTION annual meeting! 🙌
Reflected on 2 years of growth & scientific insights, and set course for the next 2 years.
Next step: making our 3 clinical trials – and project MOTION as a whole – an outstanding success! 💫
#MotionProject #TeamScience #ClinicalTrials
Reflected on 2 years of growth & scientific insights, and set course for the next 2 years.
Next step: making our 3 clinical trials – and project MOTION as a whole – an outstanding success! 💫
#MotionProject #TeamScience #ClinicalTrials
👋 After a short break, we continue to introduce our WPs to you👋
Next one is MOTION WP 4 led and introduced by
@mattiasmandorfer.bsky.social
- Comparing #HVPG responses of our medication within our clinical trials to NSBBS...
🌐More info in the video below 📷🔽
Next one is MOTION WP 4 led and introduced by
@mattiasmandorfer.bsky.social
- Comparing #HVPG responses of our medication within our clinical trials to NSBBS...
🌐More info in the video below 📷🔽
July 3, 2025 at 8:59 AM
👋 After a short break, we continue to introduce our WPs to you👋
Next one is MOTION WP 4 led and introduced by
@mattiasmandorfer.bsky.social
- Comparing #HVPG responses of our medication within our clinical trials to NSBBS...
🌐More info in the video below 📷🔽
Next one is MOTION WP 4 led and introduced by
@mattiasmandorfer.bsky.social
- Comparing #HVPG responses of our medication within our clinical trials to NSBBS...
🌐More info in the video below 📷🔽
💫This week we are introducing WP4 & WP5 💫
Focused on HVPG response to therapy, NIT-based prognostic models, & clinical outcomes in #ACLD/#PSVD.
🔬 A comprehensive approach to #hepatology research.
Led by @mattiasmandorfer.bsky.social & @mathiasjachs.bsky.social
📷More info in the graphic 📷
Focused on HVPG response to therapy, NIT-based prognostic models, & clinical outcomes in #ACLD/#PSVD.
🔬 A comprehensive approach to #hepatology research.
Led by @mattiasmandorfer.bsky.social & @mathiasjachs.bsky.social
📷More info in the graphic 📷
June 6, 2025 at 9:10 AM
💫This week we are introducing WP4 & WP5 💫
Focused on HVPG response to therapy, NIT-based prognostic models, & clinical outcomes in #ACLD/#PSVD.
🔬 A comprehensive approach to #hepatology research.
Led by @mattiasmandorfer.bsky.social & @mathiasjachs.bsky.social
📷More info in the graphic 📷
Focused on HVPG response to therapy, NIT-based prognostic models, & clinical outcomes in #ACLD/#PSVD.
🔬 A comprehensive approach to #hepatology research.
Led by @mattiasmandorfer.bsky.social & @mathiasjachs.bsky.social
📷More info in the graphic 📷
🎥 Say hi to Work Package 3 of the #MotionProject!
WP lead Dr. Georg Semmler gives a quick introduction into how we’re tackling PSVD—from molecular insights to clinical impact. 💡
Watch now & learn more about our mission in hepatology!
#WP3 #LiverResearch #PSVD #ScienceInMotion
WP lead Dr. Georg Semmler gives a quick introduction into how we’re tackling PSVD—from molecular insights to clinical impact. 💡
Watch now & learn more about our mission in hepatology!
#WP3 #LiverResearch #PSVD #ScienceInMotion
May 30, 2025 at 6:34 AM
🎥 Say hi to Work Package 3 of the #MotionProject!
WP lead Dr. Georg Semmler gives a quick introduction into how we’re tackling PSVD—from molecular insights to clinical impact. 💡
Watch now & learn more about our mission in hepatology!
#WP3 #LiverResearch #PSVD #ScienceInMotion
WP lead Dr. Georg Semmler gives a quick introduction into how we’re tackling PSVD—from molecular insights to clinical impact. 💡
Watch now & learn more about our mission in hepatology!
#WP3 #LiverResearch #PSVD #ScienceInMotion
🧬 WELCOME to WP3, In this WP we're exploring the molecular & prognostic characterization of PSVD using histology, metabolomics & RNA-seq.
The key element: the EXPOSURE trial, investigating anticoagulation with Edoxaban in PSVD patients.
#MotionProject #PSVD #WP3 #LiverResearch #ClinicalTrials
The key element: the EXPOSURE trial, investigating anticoagulation with Edoxaban in PSVD patients.
#MotionProject #PSVD #WP3 #LiverResearch #ClinicalTrials
May 22, 2025 at 8:16 AM
🧬 WELCOME to WP3, In this WP we're exploring the molecular & prognostic characterization of PSVD using histology, metabolomics & RNA-seq.
The key element: the EXPOSURE trial, investigating anticoagulation with Edoxaban in PSVD patients.
#MotionProject #PSVD #WP3 #LiverResearch #ClinicalTrials
The key element: the EXPOSURE trial, investigating anticoagulation with Edoxaban in PSVD patients.
#MotionProject #PSVD #WP3 #LiverResearch #ClinicalTrials
🌐 Introducing MOTION WorkPackage 2 by @reibergerthomas.bsky.social 🌐
In this particular WP the team is focusing on decompensated cirrhosis..
#liver #PortalHypertension #clinicaltrails #dACLD
🔽 Find out more in the video below 📷🔽
In this particular WP the team is focusing on decompensated cirrhosis..
#liver #PortalHypertension #clinicaltrails #dACLD
🔽 Find out more in the video below 📷🔽
May 16, 2025 at 9:28 AM
🌐 Introducing MOTION WorkPackage 2 by @reibergerthomas.bsky.social 🌐
In this particular WP the team is focusing on decompensated cirrhosis..
#liver #PortalHypertension #clinicaltrails #dACLD
🔽 Find out more in the video below 📷🔽
In this particular WP the team is focusing on decompensated cirrhosis..
#liver #PortalHypertension #clinicaltrails #dACLD
🔽 Find out more in the video below 📷🔽
🧠 New paper by @LorenzBalcar shows that #spleenstiffness measurement (SSM) via transient elastography helps non-invasively stratify #portalhypertension in BCR::ABL1⁻ MPN — beyond #liver stiffness.
A step forward in risk assessment!
📊👇More info 📊👇
lnkd.in/du8-FjgE
A step forward in risk assessment!
📊👇More info 📊👇
lnkd.in/du8-FjgE
May 15, 2025 at 7:44 AM
🧠 New paper by @LorenzBalcar shows that #spleenstiffness measurement (SSM) via transient elastography helps non-invasively stratify #portalhypertension in BCR::ABL1⁻ MPN — beyond #liver stiffness.
A step forward in risk assessment!
📊👇More info 📊👇
lnkd.in/du8-FjgE
A step forward in risk assessment!
📊👇More info 📊👇
lnkd.in/du8-FjgE
Some of our Motion team members are currently at #EASL2025 in Amsterdam — proudly representing our deep expertise in liver research and innovation. Come say hi if you're around! 👋
#MotionTeam #EASL2025 #LiverResearch #Innovation #ProudToRepresent
#MotionTeam #EASL2025 #LiverResearch #Innovation #ProudToRepresent
May 8, 2025 at 12:10 PM
Some of our Motion team members are currently at #EASL2025 in Amsterdam — proudly representing our deep expertise in liver research and innovation. Come say hi if you're around! 👋
#MotionTeam #EASL2025 #LiverResearch #Innovation #ProudToRepresent
#MotionTeam #EASL2025 #LiverResearch #Innovation #ProudToRepresent
#Portalhypertension Fans ⬇️
🥂🥂 OUR deputy PI
@MattiasMandorf1
.
received the "EASL Emerging Leader Awards 2025" in Amsterdam yesterday at #EALS2025
We congratulate him from the bottom of our #livers 😉 and are incredibly proud!
🥂🥂 OUR deputy PI
@MattiasMandorf1
.
received the "EASL Emerging Leader Awards 2025" in Amsterdam yesterday at #EALS2025
We congratulate him from the bottom of our #livers 😉 and are incredibly proud!
Thirteen years ago when I was still an M.D. student, I was invited for my first oral presentation at an @easlnews.bsky.social event.
🙏 to EASL for inspiration, education & support throughout this journey as well as to my mentors & friends! @bavenocoop.bsky.social #LiverSky
🙏 to EASL for inspiration, education & support throughout this journey as well as to my mentors & friends! @bavenocoop.bsky.social #LiverSky
May 8, 2025 at 4:51 AM
#Portalhypertension Fans ⬇️
🥂🥂 OUR deputy PI
@MattiasMandorf1
.
received the "EASL Emerging Leader Awards 2025" in Amsterdam yesterday at #EALS2025
We congratulate him from the bottom of our #livers 😉 and are incredibly proud!
🥂🥂 OUR deputy PI
@MattiasMandorf1
.
received the "EASL Emerging Leader Awards 2025" in Amsterdam yesterday at #EALS2025
We congratulate him from the bottom of our #livers 😉 and are incredibly proud!
🌐 MOTION Work Package 2 🌐
WP2 focuses on decompensated cirrhosis. Heart of the this wp is a clinical trial led by @reibergerthomas.bsky.social investigating the potential beneficial effects of norfloxacin in this patient group.
⬇️⬇️⬇️⬇️
#liver #liverdesease #PortalHypertension #ClinicalTrial
WP2 focuses on decompensated cirrhosis. Heart of the this wp is a clinical trial led by @reibergerthomas.bsky.social investigating the potential beneficial effects of norfloxacin in this patient group.
⬇️⬇️⬇️⬇️
#liver #liverdesease #PortalHypertension #ClinicalTrial
May 2, 2025 at 8:09 AM
🌐 MOTION Work Package 2 🌐
WP2 focuses on decompensated cirrhosis. Heart of the this wp is a clinical trial led by @reibergerthomas.bsky.social investigating the potential beneficial effects of norfloxacin in this patient group.
⬇️⬇️⬇️⬇️
#liver #liverdesease #PortalHypertension #ClinicalTrial
WP2 focuses on decompensated cirrhosis. Heart of the this wp is a clinical trial led by @reibergerthomas.bsky.social investigating the potential beneficial effects of norfloxacin in this patient group.
⬇️⬇️⬇️⬇️
#liver #liverdesease #PortalHypertension #ClinicalTrial
#liver #PortalHypertension #clinicaltrails #cACLD
Introducing MOTION WP 1 - Focusing on pathophysiological mechanisms in compensated Patients with liver cirrhosis....
🌐More info in the video below 🌐 🔽🔽
Introducing MOTION WP 1 - Focusing on pathophysiological mechanisms in compensated Patients with liver cirrhosis....
🌐More info in the video below 🌐 🔽🔽
April 25, 2025 at 7:16 AM
#liver #PortalHypertension #clinicaltrails #cACLD
Introducing MOTION WP 1 - Focusing on pathophysiological mechanisms in compensated Patients with liver cirrhosis....
🌐More info in the video below 🌐 🔽🔽
Introducing MOTION WP 1 - Focusing on pathophysiological mechanisms in compensated Patients with liver cirrhosis....
🌐More info in the video below 🌐 🔽🔽
💬Introducing WP1💬
This WP focuses on the classical & alternative renin-angiotensin system as a disease-driving mechanism in patients with cACLD. The heart of WP1 is a clinical trail to investigate potentially beneficial effects of telmisartan in this patient group.
This WP focuses on the classical & alternative renin-angiotensin system as a disease-driving mechanism in patients with cACLD. The heart of WP1 is a clinical trail to investigate potentially beneficial effects of telmisartan in this patient group.
April 22, 2025 at 6:59 AM
💬Introducing WP1💬
This WP focuses on the classical & alternative renin-angiotensin system as a disease-driving mechanism in patients with cACLD. The heart of WP1 is a clinical trail to investigate potentially beneficial effects of telmisartan in this patient group.
This WP focuses on the classical & alternative renin-angiotensin system as a disease-driving mechanism in patients with cACLD. The heart of WP1 is a clinical trail to investigate potentially beneficial effects of telmisartan in this patient group.
🌐Fridays with the MOTION Team = science, smiles & serious vibes 😎🧪
Just something else.... :) 🌐
When top-notch research meets good energy, magic happens. Work hard, laugh harder — that’s how we roll.
#MOTIONProject #ScienceSquad #FridayFeeling #TeamworkMakesTheDreamWork
Just something else.... :) 🌐
When top-notch research meets good energy, magic happens. Work hard, laugh harder — that’s how we roll.
#MOTIONProject #ScienceSquad #FridayFeeling #TeamworkMakesTheDreamWork
April 14, 2025 at 7:03 AM
🌐Fridays with the MOTION Team = science, smiles & serious vibes 😎🧪
Just something else.... :) 🌐
When top-notch research meets good energy, magic happens. Work hard, laugh harder — that’s how we roll.
#MOTIONProject #ScienceSquad #FridayFeeling #TeamworkMakesTheDreamWork
Just something else.... :) 🌐
When top-notch research meets good energy, magic happens. Work hard, laugh harder — that’s how we roll.
#MOTIONProject #ScienceSquad #FridayFeeling #TeamworkMakesTheDreamWork
🌟 Our MOTION team is growing – so are our achievements! 🌟
While knowledge is undoubtedly necessary in a project, people form the foundation of success...
Physicians, PhDstudents, PMs, StudyNurses & DataManagers bring their unique skills & perspectives that make our MOTION project truly special
While knowledge is undoubtedly necessary in a project, people form the foundation of success...
Physicians, PhDstudents, PMs, StudyNurses & DataManagers bring their unique skills & perspectives that make our MOTION project truly special
April 11, 2025 at 6:28 AM
🌟 Our MOTION team is growing – so are our achievements! 🌟
While knowledge is undoubtedly necessary in a project, people form the foundation of success...
Physicians, PhDstudents, PMs, StudyNurses & DataManagers bring their unique skills & perspectives that make our MOTION project truly special
While knowledge is undoubtedly necessary in a project, people form the foundation of success...
Physicians, PhDstudents, PMs, StudyNurses & DataManagers bring their unique skills & perspectives that make our MOTION project truly special
🥳🥳 Proud to announce that another VLSG member Nikolaus Pfisterer has successfully defended his #PhD at @meduniwien.ac.at
🙌🙌🙌 Congrats and let's celebrate!! 🙌🙌🙌
🙌🙌🙌 Congrats and let's celebrate!! 🙌🙌🙌
🎓MD #PhD Nikolaus Pfisterer @MedUni_Wien
#liver research @ViennaLiverNews @crgmotion.bsky.social
1⃣ #NSBB improve survival in 2nd🩸prophylaxis
@APandT 🔗 t.ly/tcZ1q
2⃣ #SEMS stent controls severe variceal🩸bleeding
@LiverInt 🔗 t.ly/wcDLo
2⃣ #EVL is safe in ⤵️PLT and ⤴️INR
@HepInt 🔗 t.ly/yKfuT
#liver research @ViennaLiverNews @crgmotion.bsky.social
1⃣ #NSBB improve survival in 2nd🩸prophylaxis
@APandT 🔗 t.ly/tcZ1q
2⃣ #SEMS stent controls severe variceal🩸bleeding
@LiverInt 🔗 t.ly/wcDLo
2⃣ #EVL is safe in ⤵️PLT and ⤴️INR
@HepInt 🔗 t.ly/yKfuT
April 9, 2025 at 10:10 AM
🥳🥳 Proud to announce that another VLSG member Nikolaus Pfisterer has successfully defended his #PhD at @meduniwien.ac.at
🙌🙌🙌 Congrats and let's celebrate!! 🙌🙌🙌
🙌🙌🙌 Congrats and let's celebrate!! 🙌🙌🙌
MEET the MOTION Team!
A team of clinical & basic researchers, assembled by @reibergerthomas.bsky.social & @mattiasmandorfer.bsky.social to conduct clinical studies & translational research on PH-driving molecular mechanisms.
Those aspiring members are divided in 8 WPs assigned to their expertise.
A team of clinical & basic researchers, assembled by @reibergerthomas.bsky.social & @mattiasmandorfer.bsky.social to conduct clinical studies & translational research on PH-driving molecular mechanisms.
Those aspiring members are divided in 8 WPs assigned to their expertise.
April 2, 2025 at 10:40 AM
MEET the MOTION Team!
A team of clinical & basic researchers, assembled by @reibergerthomas.bsky.social & @mattiasmandorfer.bsky.social to conduct clinical studies & translational research on PH-driving molecular mechanisms.
Those aspiring members are divided in 8 WPs assigned to their expertise.
A team of clinical & basic researchers, assembled by @reibergerthomas.bsky.social & @mattiasmandorfer.bsky.social to conduct clinical studies & translational research on PH-driving molecular mechanisms.
Those aspiring members are divided in 8 WPs assigned to their expertise.
#PortalHypertension Fans !! #liver 👍
We are thrilled to share that our clinical trial is in full swing!
It is divided in 8 work packages and over the upcoming weeks, we’ll introduce each innovative work package, with the dedicated experts, driving this project forward.
⬇️📷More info 📷⬇️
We are thrilled to share that our clinical trial is in full swing!
It is divided in 8 work packages and over the upcoming weeks, we’ll introduce each innovative work package, with the dedicated experts, driving this project forward.
⬇️📷More info 📷⬇️
March 28, 2025 at 7:42 AM
#PortalHypertension Fans !! #liver 👍
We are thrilled to share that our clinical trial is in full swing!
It is divided in 8 work packages and over the upcoming weeks, we’ll introduce each innovative work package, with the dedicated experts, driving this project forward.
⬇️📷More info 📷⬇️
We are thrilled to share that our clinical trial is in full swing!
It is divided in 8 work packages and over the upcoming weeks, we’ll introduce each innovative work package, with the dedicated experts, driving this project forward.
⬇️📷More info 📷⬇️
🚀 Behind the abbreviation MOTION is a top-tier clinical research group at MedUni Vienna tackling portal hypertension – the key driver of liver disease morbidity & mortality. 🔬
⬇️ Follow for more info... ⬇️
#portalhypertension #research #clinicaltrail #liver #blueskyliver
⬇️ Follow for more info... ⬇️
#portalhypertension #research #clinicaltrail #liver #blueskyliver
March 20, 2025 at 10:37 AM
🚀 Behind the abbreviation MOTION is a top-tier clinical research group at MedUni Vienna tackling portal hypertension – the key driver of liver disease morbidity & mortality. 🔬
⬇️ Follow for more info... ⬇️
#portalhypertension #research #clinicaltrail #liver #blueskyliver
⬇️ Follow for more info... ⬇️
#portalhypertension #research #clinicaltrail #liver #blueskyliver